Suchergebnisse - "Colorectal"

PubPharm (119.252)

91

Causal association between urine albumin-to-creatinine ratio and risk of colorectal cancer : A two-sample Mendelian randomization study

enthalten in: Physiology international | 2024

von Gao, X. | Chen, Y.

92

Lifetime prevalence and correlates of colorectal cancer screening among low-income U.S. Veterans

enthalten in: Cancer causes & control : CCC | 2024

von Beydoun, H. | Tsai, J.

93

CircHIF1A induces cetuximab resistance in colorectal cancer by promoting HIF1α-mediated glycometabolism alteration

enthalten in: Biology direct | 2024

von Geng, Y. | Zheng, X. | Zhang, D. | +6

94

Trends in patterns of treatment and survival of colorectal cancer patients using cancer registry data in Japan : 1995-2015

enthalten in: Cancer science | 2024

von Ota, M. | Taniguchi, K. | Hori, M. | +6

95

Colorectal cancer subtyping and immune landscape analysis based on natural killer cell-related genes

enthalten in: Arab journal of gastroenterology : the official publication of the Pan-Arab Association of Gastroenterology | 2024

von Ding, M. | Gao, J. | Wang, J. | +7

96

Robotic ambulatory colorectal resections: a systematic review

enthalten in: Journal of robotic surgery | 2024

von Ho, J. | Goel, A. | Fung, A. | +2

97

CircHIF1A induces cetuximab resistance in colorectal cancer by promoting HIF1α-mediated glycometabolism alteration

enthalten in: Biology direct | 2024

von Geng, Y. | Zheng, X. | Zhang, D. | +6

98

Evaluation for NCI Surgery Branch Clinical Research Protocols : Evaluation for NCI Surgery Branch Clinical Research Protocols

enthalten in: ClinicalTrials.gov | 2024

99

A Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer (mCRC) : A Multi-Centre Randomised Clinical Trial of Biomarker-Driven Maintenance Treatment for First-Line Metastatic Colorectal Cancer (MODUL)

enthalten in: ClinicalTrials.gov | 2024

100

Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer, the COMMIT Study : Colorectal Cancer Metastatic dMMR/MSI-H Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab/Atezolizumab Combination Versus Single Agent Atezolizumab in the First-Line Treatment of Patients With Deficient DNA Mismatch Repair (dMMR)/Microsatellite Instability-High (MSI-H) Metastatic Colorectal Cancer

enthalten in: ClinicalTrials.gov | 2024